$HURA Cashflow Statement | Understand Stock

$HURA

$2.04 -$0.14 (6.42%) Close

$HURA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Jun 30, 2024	FY2022 12 months to Jun 30, 2023	FY2021 12 months to Jun 30, 2022
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation of property and equipment
Amortization of intangible assets
Amortization of clinical trial deposit
Change in fair value of milestone liability
Interest expense
Warrants issued for services
Restricted stock units and shares issued for services
Stock option expense
Stock compensation expense
Depreciation and amortization
Amortization of debt discount
Loss on share issuance to Kineta separation payments
Change in fair value of holdback shares
Change in fair value of derivative liability

Changes in operating assets and liabilities
Prepaid expenses, deposits and other
Clinical trial deposits
Other current assets
Other noncurrent assets
Accounts payable and accrued expenses
Related party payables
Net cash flows from operating activities
Cash flows from investing activities:
Deposits, planned business acquisition
Cash paid for Kineta acquisition, net of assumed cash
Purchase of property and equipment
Net cash flows from investing activities
Cash flows from financing activities:
Net proceeds from the issuance of shares and warrants
Series A Preferred dividend
Repayment of assumed Kineta indeptedness
Payments made on Kineta severance promissory notes
Payments on equipment lease
Proceeds from convertible notes payable
Proceeds from bridge note
Payment of bridge note
Proceeds from stock options exercised
Proceeds from warrants exercised
Payment of offering costs associated with issuance of common stock
Payment of merger transaction costs
Payment of debt issuance costs
Payment of net liabilities assumed in reverse recapitalization
Net cash flows from financing activities
Net change in cash and cash equivalents
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year
Supplemental disclosure of cash flow information
Cash paid for interest
Supplemental non-cash activity
Right-of-use asset recognized in exchange for operating lease obligations
Right-of-use asset recognized in exchange for finance lease obligations
Deferred offering costs not yet paid
Consideration for Kineta acquisition issued in shares
Net liabilities assumed in reverse recapitalization not yet paid
Merger transaction costs not yet paid
Derivative liability associated with make-whole premium
Fair value of warrants associated with convertible notes payable
Warrants issued recorded as a debt discount
Deemed dividend on warrant modifications
Issuance of common stock for placement agent fees
Preferred Series A cash dividend not yet paid
Fair value of contingent value rights associated with reverse recapitalization
Fair value of warrants issued to financial advisor
Shares issued for placement agent fees
Contingent value rights associated with Kintara merger
Warrants issued to financial advisor
Shares issued for payment of bridge note
Shares issued upon settlement of convertible notes

Comments